CORRECTION -- Biodel Reports Positive Top-Line Results From Clinical Study Of Ultra-Rapid-Acting Insulin Analog Candidates

DANBURY, Conn., Jan. 24, 2013 (GLOBE NEWSWIRE) -- In a release issued earlier today by Biodel Inc. (Nasdaq:BIOD), one reference to BIOD-238 should have been BIOD-250 in the fourth paragraph. The corrected paragraph follows:

Local injection site discomfort was measured with a 100 mm visual analog scale (VAS) and patient questionnaires. 100 mm is defined as the worst possible discomfort and 0 mm is defined a having no discomfort. In the trial, the VAS score was numerically lower, but not significantly different for BIOD-250 compared to Humalog ® (mean VAS scores of 2.7 mm and 8.2 mm for BIOD-250 and Humalog ®, respectively; p=NS). The VAS score for BIOD-238 was significantly higher than that associated with Humalog ® (mean VAS score of 24.2 mm, p=0.029 vs. Humalog ®).

BIOD-G
CONTACT: Seth D. Lewis, +1-646-378-2952

If you liked this article you might like

3 Biotech Stocks Under $10 to Trade for Big Gains

3 Biotech Stocks Under $10 to Trade for Big Gains

5 Stocks Under $10 Set to Soar: Must-See Charts

5 Stocks Under $10 Set to Soar: Must-See Charts

4 Stocks Under $10 Making Big Moves Higher

4 Stocks Under $10 Making Big Moves Higher

3 Breakout Biotech Stocks Trading for Under $10

3 Breakout Biotech Stocks Trading for Under $10

5 Stocks Under $10 Set to Soar

5 Stocks Under $10 Set to Soar